The Food and Drug Administration on Friday approved the first drug that benefits patients with lung cancer caused by a specific genetic mutation to a protein called KRAS, a target that for decades was considered to be “undruggable.”
The new medicine, a pill called Lumakras, was developed by Amgen.
About the Author Reprints
